Welcome
BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The Company's pipeline currently includes product candidates for the treatment of cancer, thrombosis and atherosclerosis.
BioInvent shortlisted for SCRIP awardsBioInvent is shortlisted for the SCRIP awards "Licensing Deal of the Year" and "Management Team of the Year". Read more » |
|
Meet Us At
17th Annual BioPartnering Europe 11-13 October
2009, London UK
International Pharmaceutical Licensing Symposium
28-30 October 2009, Rome, Italy
Our Pipeline
BioInvent develops antibody-based drugs to tackle conditions where there is a significant need for new treatments. We currently have four antibody therapeutics in development. Find out more »
Latest Company News
Latest Share Price
Clinical Trials
BioInvent is currently running a number of early-stage clinical trials with several of its products. Click here to find out more »